pharmaphorum

JUNE 23, 2022

Novartis has shouldered its way into the in vivo gene editing category via a deal with US biotech Precision BioSciences, focused on a therapy for sickle cell disease (SCD). It is also working with Eli Lilly on in vivo gene-editing drugs against three targets, including one in Duchenne muscular dystrophy, under the terms of a $1.4

Gene Editing 97

Gene Editing In-Vivo Gene Sequencing Gene 97

pharmaphorum

DECEMBER 14, 2022

The two partners have revealed the first clinical data from a phase 2b trial of a personalised vaccine consisting of 34 mRNAs, each targeting mutations – identified by gene sequencing – that are thought to be driving a patient’s cancer. They also said they plan to discuss the phase 2b results with regulators.

Vaccination 98

Vaccination Vaccine Trials Gene Sequencing 98

pharmaphorum

SEPTEMBER 14, 2022

SparingVision has raised €75 million in second-round funding that will be used to fund clinical trials of gene therapies for ocular diseases retinitis pigmentosa (RP) and dry age-related macular degeneration (AMD). The current schedule is for trials to start in 2024, with first safety and efficacy data coming a year later.

Gene Therapy 52

Gene Therapy Gene Gene Sequencing Gene Editing 52

pharmaphorum

MARCH 10, 2022

18 months after signing its first partnering deal with Genentech, Scenic Biotech has raised $31 million in first-round financing that it will use to take its own genetic modifier-targeted medicines into clinical trials.

Genetics 98

Genetics Gene Sequencing Gene Clinical Trials 98

pharmaphorum

MARCH 15, 2022

Gene sequencing specialist Illumina has started rolling out a new test that looks for a battery of tumour-associated genes from a single tissue sample, and could be used to help guide treatment for a broad range of cancers. The post Illumina debuts its multi-gene test for cancer in Europe appeared first on.

Gene 52

Gene Genomics Genome Gene Sequencing 52

pharmaphorum

JANUARY 5, 2023

The data was from their phase 2b trial of a personalised vaccine consisting of 34 mRNAs, each targeting mutations – identified by gene sequencing – thought to be driving a patient’s cancer. The post Boost for mRNA as Moderna to acquire OriCiro for $85 million appeared first on.

Gene Sequencing 97

Gene Sequencing DNA Vaccine Vaccination 97

pharmaphorum

OCTOBER 12, 2022

The neoantigens are selected based on gene sequencing of either a tumour biopsy or a blood sample, with an individual vaccine tailored to the patient manufactured and administered in a matter of weeks.

Vaccination 105

Vaccination Vaccine Gene Sequencing RNA 105